Efficacy of adjuvant chemotherapy for elderly patients with colon cancer

• DOI: 10.1093/annonc/mdy151.231
• Publication Date: 2018-06-20T06:14:05Z
• Authors: M. Villamayor Del...; C. Saavedra Serrano; E. Corral de la F...; A. Barquín García; O. Martínez Saez; R. Martín Huertas; J. Serrano Domingo; J. Molina Cerrillo; F. Longo Muñoz; V. Pachón Olmos; M. Rodriguez Garrote; P. Reguera Puertas; M. Vaz; A. Carrato; R. Ferreiro Monte...
• Keywords: 0502 economics and business; 05 social sciences

Introduction: The benefit of adjuvant chemotherapy (fluoracil or capecitabine with without oxaliplatin) has been well established in the setting for node-positive colon cancer (stage III). extent to which older adults from was not different trials (MOSAIC, NSABP C-07, N016968) given that there no participation patients than 75 years old. However, latest published systematic reviews are contradictory results on efficacy this population. Methods: We retrospectively included stages II and III underwent surgical treatment between 2009 2014 at University Hospital Ramón y Cajal (Madrid). calculated DFS OS 48 months we performed a univariate multivariate Cox model analysis estimate age groups (cut-off point 70 years) stage diagnosis. further adjusted by including following confounding factors: ECOG-PS, grade, number resected nodes, CEA before surgery, side location, presence obstruction/perforation. A covariate considered factor if difference unadjusted coefficient varied> 10%. Stata 13.1 used analyse data. Results: 551 were identified (166 <70 old 385 ≥ old). 281 (51%) 220 270 (49%) 165 In addition, had ECOG-PS: 0 but 331 ECOG-PS greater (43%, 1). 248 received 303 did not. median follow-up entire cohort 49 months. reached moment analysis. both 78.5%. Globally, improve (HR 0, 72, p 43) significantly better 36, 0,005). By stage, (HR: 67, p: 0.2) nor 0.4, 0.085). III, showed trend de 23, 58) clearly 0,071, 0,002). Nevertheless, global population shows 0,657 0,031) 0,257 (IC: 0,149 – 0,445) 0,002) probably affected factors (ECOG-PS, obstruction/perforation nodes). Conclusion: multivariable cancer, 77% reduction risk recurrence 29% death. these benefits found either PFS OS. More prospective studies group needed confirm findings.